Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Has Average Price Target of $65.50 According to Brokerages

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has been assigned an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $65.50.

RIGL has been the subject of several research reports. Piper Sandler reiterated a “neutral” rating and set a $49.00 price target (up from $40.00) on shares of Rigel Pharmaceuticals in a research note on Monday, August 17th. Citigroup restated a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Thursday, August 6th. Cantor Fitzgerald upped their price objective on shares of Rigel Pharmaceuticals from $43.00 to $47.00 and gave the company a “neutral” rating in a report on Friday. Weiss Ratings raised shares of Rigel Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, Zacks Research lowered shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 14th.

Institutional Trading of Rigel Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Allworth Financial LP boosted its holdings in Rigel Pharmaceuticals by 103.7% in the 3rd quarter. Allworth Financial LP now owns 982 shares of the biotechnology company’s stock worth $47,000 after buying an additional 500 shares during the period. Ritholtz Wealth Management raised its holdings in Rigel Pharmaceuticals by 13.9% during the 3rd quarter. Ritholtz Wealth Management now owns 107,590 shares of the biotechnology company’s stock valued at $5,180,000 after acquiring an additional 13,140 shares during the period. Knights of Columbus Asset Advisors LLC bought a new stake in Rigel Pharmaceuticals during the 3rd quarter valued at $1,465,000. Signature Equity Partners LLC bought a new stake in Rigel Pharmaceuticals during the 3rd quarter valued at $27,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Rigel Pharmaceuticals during the third quarter worth $46,000. 66.23% of the stock is currently owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals News Roundup

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue was $80.9 million, just above the $80.1 million expected, and Rigel reported $13.2 million in net income. Newly launched VEPPANU generated $6.6 million in initial sales after becoming commercially available in mid-August. Rigel Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Cantor Fitzgerald lifted its price target to $47 from $43, while maintaining a neutral rating. Cantor Fitzgerald price target
• Negative Sentiment: Adjusted earnings were $0.65 per share, missing analyst estimates of roughly $0.87–$0.92 and falling from $1.46 a year earlier. The earnings shortfall is the clearest near-term negative for the stock. Rigel Pharmaceuticals misses Q3 earnings estimates

Rigel Pharmaceuticals Stock Performance

Shares of NASDAQ RIGL opened at $39.65 on Monday. The stock has a fifty day simple moving average of $47.79 and a two-hundred day simple moving average of $37.47. Rigel Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $52.60. The firm has a market cap of $733.52 million, a price-to-earnings ratio of 2.56 and a beta of 1.28.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.27). The firm had revenue of $80.89 million during the quarter, compared to the consensus estimate of $80.10 million. Rigel Pharmaceuticals had a net margin of 106.59% and a return on equity of 15.25%. Analysts forecast that Rigel Pharmaceuticals will post 2.98 EPS for the current year.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel’s primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.